Telomerase reverse transcriptase (TERT) is moving to the center of aging research, framed by a new Perspective by Richard DePinho as a potential “apex” regulator linking multiple hallmarks of aging. While telomerase is best known for protecting chromosome ends, TERT appears to do more than lengthen telomeres. In preclinical systems, TERT has been implicated in mitochondrial integrity, epigenetic control, inflammatory setpoints, and stem-cell maintenance—pathways that collectively shape healthspan.
A central message in the article is that TERT’s influence can extend beyond its canonical telomere role. Mechanistically, TERT has been proposed to intersect with cellular stress responses and metabolic programs, contributing to more resilient mitochondrial function. It also appears capable of affecting chromatin-associated processes, potentially altering how genes governing aging-related phenotypes are expressed over time. These noncanonical effects could help explain why telomerase-linked interventions sometimes produce broad, multi-system improvements rather than purely chromosome-end protection.
Translational strategies, the Perspective notes, are increasingly focused on restoring TERT activity toward physiological levels rather than forcing maximal telomerase expression. In mouse studies and human cell models, re-establishing TERT expression in ranges characteristic of younger biology—and related telomere-targeted approaches—has been associated with improvements in selected age-associated phenotypes. Importantly for the field, these gains have often been reported without a detectable increase in cancer, a key consideration for any geroprotective approach.
At the same time, human genetics introduces a caution flag. Common genetic variation in the TERT locus is linked with higher risk for several cancers, reinforcing that manipulating TERT is not a purely “anti-aging” switch. The Perspective argues that mechanistic studies must clarify how different TERT states—levels, localization, and downstream partners—translate into both tissue rejuvenation and tumorigenic risk.
The author places emphasis on long-term safety evaluation and careful therapeutic design. Because cancer risk may depend on context, cell type, and duration of TERT modulation, interventions likely require fine-tuned dosing, temporal control, and rigorous monitoring. “Cautious therapeutic framework” is the guiding theme: demonstrate geroprotective signals, characterize telomere and non-telomere biology, and stress-test for oncogenic outcomes.
Ultimately, the Perspective suggests that TERT occupies an influential position in aging biology with plausible leverage over healthspan. But turning that promise into a real therapy will demand durability of benefits, mechanistic clarity, and a safety case robust enough to withstand years—not months—of follow-up.
Subject of Research: TERT as an upstream regulator of aging and a candidate target for geroprotective therapies
Article Title: Positioning TERT at the apex of aging
Article References: DePinho, R.A. Positioning TERT at the apex of aging. Nat Aging (2026). https://doi.org/10.1038/s43587-026-01179-y
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s43587-026-01179-y
Keywords: TERT, telomerase, aging, healthspan, epigenetics, mitochondria, inflammation, cancer risk
